Ionis Pharmaceuticals (IONS) stock is in focus after the company completed enrollment in the pivotal pediatric cohort of its global Phase 3 REVEAL study of obudanersen for Angelman syndrome, a rare neurodevelopmental disorder.

The recent pediatric cohort milestone for obudanersen comes on top of an eventful few weeks for Ionis Pharmaceuticals, including FDA approval of TRYNGOLZA and a new zilganersen licensing deal. During this period the stock posted a 30 day share price return of 9.83% and a 1 year total shareholder return of 95.79%, suggesting momentum has been building as investors reassess both growth prospects and risk.

If this kind of rare disease and RNA medicine story interests you, it can be worth seeing what else is moving in similar areas through the 40 healthcare AI stocks.

After a near doubling in Ionis Pharmaceuticals’ total return over the past year and fresh wins around TRYNGOLZA and obudanersen, the key tension now is clear: is most of the rerating done, or is the valuation still leaving meaningful upside on the table?

Most Popular Narrative: 18.9% Undervalued

Ionis Pharmaceuticals last closed at $81.80, while the most followed narrative anchors fair value at $100.92, framing the current share price as a discount.

The rapid revenue growth and positive launch trajectory for Tryngolza in familial chylomicronemia syndrome (FCS), along with the imminent launch of Donidalorsen for HAE and multiple late-stage pipeline assets reading out or launching by 2027, are set to drive sustained, stepwise increases in top-line revenue and operating leverage as Ionis transitions from R&D-heavy to commercial-stage.

If you are curious what kind of revenue ramp, margin lift, and earnings profile are built into that $100.92 fair value, and how sensitive it is to a few big programs, the narrative lays out the full financial blueprint behind that valuation call.

Result: Fair Value of $100.92 (UNDERVALUED)

However, Ionis Pharmaceuticals still carries real execution risk, with heavy dependence on a few late stage assets and exposure to potential pricing pressure as indications broaden.

Another View: Ionis Pharmaceuticals Through a Sales Multiple Lens

While the SWS DCF model flags Ionis Pharmaceuticals as trading 76.4% below its estimated future cash flow value of $346.02, the picture changes when you look at current sales. At a P/S ratio of 12.8x versus a fair ratio of 6.3x, and higher than both peers on 5.3x and the US Biotechs industry on 12x, the stock screens as expensive on today’s revenue. For investors, that raises a simple question: which signal deserves more weight right now?

Next Steps

With sentiment clearly split on Ionis Pharmaceuticals, this is the moment to move quickly, review the underlying data and test your own thesis against the 3 key rewards.

Looking For More Ideas Beyond Ionis Pharmaceuticals?

If Ionis Pharmaceuticals has sharpened your interest in focused, thesis driven investing, do not stop here. Broaden your watchlist now using targeted stock ideas.

• Spot potential value opportunities early by reviewing companies screened as 44 high quality undervalued stocks before the crowd fully pays attention.
• Strengthen your core holdings by shortlisting companies from the solid balance sheet and fundamentals stocks screener (47 results) that emphasize financial resilience.
• Catch underfollowed stories by scanning the screener containing 18 high quality undiscovered gems that pair fundamentals with relatively low investor attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.